Prosigna® - Breast Cancer Prognostic Gene Signature Assay
Prosigna® is indicated for in vitro diagnostic use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II), or node-positive (Stage II) breast cancer to be treated with adjuvant endocrine therapy for assessment of risk of distant recurrence of disease.
Prosigna® Breast Cancer Prognostic Gene Signature Assay for use on the Nanostring nCounter® Dx Analysis System is 510(k) cleared and CE-marked for in vitro diagnostic use in the United States and EU, respectively. See Package Insert for details
Link to Prosigna®